IL6 and COVID-19: Nevertheless, tofacitinib, a Janus kinase inhibitor which suppresses Th1 response and IL-6 production has recently been shown to decrease mortality in patients hospitalized with COVID-19 even when the majority of patients were already given corticosteroids (19, 58).